Abstract Details

Title Relapse in Patients with Multiple Sclerosis Newly Initiating scIFN?1a Compared with Oral Disease-Modifying Drugs: A Real-World Assessment

Topic Multiple Sclerosis

Presentation(s) P1 - (-)

Poster/Presentation
Number 353

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
James D. Bowen, MD (Swedish Neuroscience Institute) PRESENTER	Dr. Bowen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen IDEC. Dr. Bowen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for BristolMyers Squibb. Dr. Bowen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Bowen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. Bowen has received research support from Biogen IDEC. The institution of Dr. Bowen has received research support from Genentech. The institution of Dr. Bowen has received research support from Genzyme. The institution of Dr. Bowen has received research support from Novartis. The institution of Dr. Bowen has received research support from Roche.
	No disclosure on file
Megan Grosso	No disclosure on file
Amy L. Phillips, PharmD (EMD Serono)	Amy L. Phillips, PharmD has received personal compensation for serving as an employee of EMD Serono, Inc.